MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-28-2026
InMode Ltd. Revenue 2011-2026 | INMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue InMode Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 358 M | 206 M | 156 M | 100 M | 53.5 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 358 M | 53.5 M | 175 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 12.42 | -4.46 % | $ 1.86 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 38.55 | 0.13 % | $ 5.74 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.31 | 1.4 % | $ 597 M |  Israel |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 9.61 | -0.62 % | $ 1.3 B | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Electromed
ELMD
|
64 M | $ 24.26 | -0.12 % | $ 205 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 41.66 | -3.09 % | $ 1.29 B | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.19 | -1.41 % | $ 156 M |  France |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.59 | 0.3 % | $ 122 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 29.15 | -0.24 % | $ 1.34 B | USA |
 |
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.27 | -0.82 % | $ 113 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
459 M | $ 0.5 | -4.78 % | $ 51.4 M | USA |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.81 | 1.91 % | $ 44.1 M | USA |
 |
Align Technology
ALGN
|
4 B | $ 175.78 | -3.51 % | $ 13.2 B | USA |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 3.7 | -8.31 % | $ 783 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 110.91 | -1.94 % | $ 193 B | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 72.61 | 0.55 % | $ 107 B | USA |
 |
IRadimed Corporation
IRMD
|
73.2 M | $ 100.27 | -4.6 % | $ 1.27 B | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.4 | -0.71 % | $ 22.6 M | USA |
 |
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.61 | 12.07 % | $ 63 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.55 | -5.03 % | $ 412 M | USA |
 |
Medtronic PLC
MDT
|
33.5 B | $ 92.93 | -2.8 % | $ 119 B | USA |
 |
Helius Medical Technologies
HSDT
|
644 K | $ 2.26 | -2.16 % | $ 1.37 M | USA |
 |
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 83.7 | -1.78 % | $ 48.9 B | USA |